文献速递细胞病理与分子病理消化与肝胆胰病理

基于WHO胰胆细胞病理报告系统的胆道细胞学恶性风险

Risk of malignancy for biliary cytology based on World Health Organization (WHO) reporting system for pancreaticobiliary cytopathology.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

该回顾性研究纳入1056例胆道细胞学病例(789例患者),按WHO胰胆细胞病理分类评估恶性风险(ROM)。胆道刷检/冲洗和FNA的绝对ROM在WHO I至III类较高,高级别(V-VII)类别恶性比值比显著升高。低级别病变罕见阻碍了Pan-low(WHO IV)的ROM评估,Pan-high(WHO V)的临床价值因高级别非浸润性病变罕见和细胞学诊断困难而不确定。

要点

  • 胆道细胞学WHO I-III类的绝对恶性风险较高,部分因取样困难。
  • 高级别(V-VII)类别无论活检方式、支架或自身免疫性胆管炎,恶性比值比均显著升高。
  • Pan-low(WHO IV)和Pan-high(WHO V)的ROM评估受限,临床价值待明确。

核心结论

  • 胆道病变WHO I至III类的绝对恶性风险较高,部分因取样癌症困难,尤其是外压性梗阻胆管者。
  • 低级别胆道病变罕见,阻碍Pan-low(WHO IV)的绝对恶性风险评估。
  • Pan-high(WHO V)的临床价值因高级别非浸润性病变罕见和细胞学诊断困难而不确定。

研究设计与样本

  • 回顾性收集2016至2019年诊断的胆道细胞学数据,共1056例(来自789例患者)。
  • 样本类型:胆道刷检/冲洗757例(72%),FNA 115例(11%),其他184例(17%)。
  • 同部位组织学对照292例(28%),转移灶组织学124例(12%)。
  • 排除无组织学且临床随访不足3个月的病例后,计算ROM、比值比、性能特征和总生存。

主要发现

  • 789例患者中704例(89%)出现恶性结局。
  • 胆道刷检/冲洗的WHO I至VII类绝对ROM分别为92%、72%、87%、0%、100%、94%、100%。
  • FNA的WHO I至VII类绝对ROM分别为50%、46%、73%、不适用、100%、80%、100%。
  • 良性病例中位随访1431天。

关键数值与推荐

  • 高级别(V-VII)类别无论活检方式、支架存在或自身免疫性胆管炎,恶性比值比均显著升高。
  • 胆道刷检/冲洗WHO I至VII类绝对ROM:92%、72%、87%、0%、100%、94%、100%。
  • FNA WHO I至VII类绝对ROM:50%、46%、73%、不适用、100%、80%、100%。

临床怎么用

  • 胆道细胞学报告应采用WHO胰胆分类系统,明确ROM分层。
  • 高级别(V-VII)类别提示恶性风险显著增高,应结合临床积极处理。
  • Pan-low(WHO IV)因病变罕见,ROM评估需谨慎,避免过度解读。

局限性

  • 低级别胆道病变罕见,限制Pan-low(WHO IV)的ROM评估。
  • 高级别非浸润性病变罕见且细胞学诊断困难,Pan-high(WHO V)临床价值不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization (WHO) classification for pancreaticobiliary cytopathology stratifies risk of malignancy (ROM) and outcome for pancreatic fine-needle aspirations (FNAs). ROM for biliary cytology, particularly for WHO categories Pan-low (IV) and Pan-high (V), has not been well examined. METHODS: Retrospective data of biliary cytology diagnosed from 2016 to 2019 were collected. WHO classification was assigned. Malignant outcome was determined by histologic correlation or clinical progression/death. Excluding clinical follow-up <3 months (if no histology), the ROM, odds ratio, performance characteristics, and overall survival were calculated. RESULTS: A total of 1056 biliary cytology cases (from 789 patients) were included. Sample types were: 757 (72%) biliary brush/wash, 115 (11%) FNA, and 184 (17%) other. Same-site histologic correlation was 292 (28%) and histology of metastasis in 124 (12%). The median follow-up (for benign) was 1431 days. Malignant outcome occurred in 704 (n = 789, 89%) of patients. Absolute ROM (%) for WHO I to VII by biliary brush/wash and FNA were: 92, 72, 87, 0, 100, 94, 100, and 50, 46, 73, N/A, 100, 80, 100, respectively. A high-tier (V-VII) category had significantly higher odds of malignancy regardless of biopsy modality, presence of stent, or autoimmune cholangitis. CONCLUSION: Absolute ROM for biliary lesions is high for WHO I through III and is at least partly because of difficulty in sampling cancers, particularly those extrinsically obstructing the bile duct. The rarity of low-grade biliary lesions impedes AROM assessment for Pan-low (WHO IV). The clinical value of biliary Pan-high (WHO V) remains uncertain because of rarity of high-grade noninvasive lesions and difficulty in cytology diagnosis.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Abraham AE, Wang X, Hargett I, et al. Risk of malignancy for biliary cytology based on World Health Organization (WHO) reporting system for pancreaticobiliary cytopathology. Cancer Cytopathol. 2026. PMID: 42142111. doi:10.1002/cncy.70109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。